TrialDiabetes, obesity & metabolism2015

Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.

M K Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.